Salta al contenuto principale
Toggle navigation
Live markets
Search
Search
Search
Search
My profile
My Subscriptions
Watchlists
Quote alerts
Create account
Sign in
IT
FR
EN
PT
NL
NB
DE
IT
Home
Company Press Releases
Company press releases
Registrati
Filtri
Filtri
Aggiorna
Ripristina
Icon After
Data
Toggle Visibility
Tutti
Oggi
Questa settimana
Questo mese
Custom date range
From
To
Topic
Toggle Visibility
Acquisition or disposal of the issuer’s own shares
Additional regulated information required to be disclosed under the laws of a Member State
Adjustment of interest rate
Alliances and agreements
Annual financial and audit Reports
Change in Capital
Changes in the rights attaching to the classes of shares or securities
Commercial operations
Commercial results
Corporate life
Dividend
Ex Date
General meeting / Board Meeting
Half yearly financial reports and audit reports/limited reviews
Home Member State
Income
Inside information
Joint venture
Journal / appointments
Legal
Major shareholding notifications
Mandatory notification of trade primary insiders
Meetings / events
Mergers, Acquiqitions, Transferts
New
New establishment
News contracts
Non-regulatory press releases
Other financial transaction
Other subject
Payments to governments
Polls / Surveys
Products and services
Prospectus / admission document
Rating
Sales
Share history
Share introduction and issues
Takeover bids
Total number of voting rights and capital
Trends / Analyses
Provider
Toggle Visibility
ActusNewsWire
BusinessWire
EQS Group
Euronext
GlobeNewswire
Les Echos
Marketwire
Modular Finance
Oslo Børs Newspoint
PR Newswire
Displaying 101 - 126 of 126 results
Released
Company
Title
Industry
Topic
19 Sep 2022
07:30 CEST
GENFIT
GENFIT : acquisition de Versantis AG, société biopharmaceutique de phase clinique, pour enrichir son portefeuille de produits dans les maladies du foie
20103010 Biotechnology
Mergers, Acquiqitions, Transferts
19 Sep 2022
07:30 CEST
GENFIT
GENFIT to Acquire Clinical-stage Biopharmaceutical Company Versantis, expanding its Portfolio in Liver Diseases
20103010 Biotechnology
Mergers, Acquiqitions, Transferts
13 Sep 2022
22:10 CEST
GENFIT
La FDA accorde la désignation d’Orphan Drug à GNS561 pour le traitement du cholangiocarcinome
20103010 Biotechnology
Other subject
13 Sep 2022
22:10 CEST
GENFIT
FDA Grants GENFIT’s GNS561 Orphan Drug Designation for the Treatment of Cholangiocarcinoma
20103010 Biotechnology
Other subject
08 Jul 2022
22:10 CEST
GENFIT
GENFIT : Bilan semestriel du contrat de liquidité contracté avec le Crédit Industriel et Commercial
20103010 Biotechnology
Other subject
08 Jul 2022
22:10 CEST
GENFIT
GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
20103010 Biotechnology
Other subject
25 May 2022
22:10 CEST
GENFIT
GENFIT: May 25, 2022 Combined Shareholders Meeting results
20103010 Biotechnology
General meeting / Board Meeting
25 May 2022
22:10 CEST
GENFIT
GENFIT : Résultats de l’Assemblée Générale Mixte du 25 mai 2022
20103010 Biotechnology
General meeting / Board Meeting
11 May 2022
22:10 CEST
GENFIT
GENFIT Reports First Quarter 2022 Financial Information (Unaudited financial information under IFRS)
20103010 Biotechnology
Other subject
11 May 2022
22:10 CEST
GENFIT
GENFIT : Information financière du premier trimestre 2022 (Données non auditées établies selon les normes IFRS)
20103010 Biotechnology
Other subject
29 Apr 2022
22:10 CEST
GENFIT
GENFIT Announces Publication of the 2021 Universal Registration Document; the 2021 Annual Report on Form 20-F and Availability of Preparatory Documents for the Annual Combined Shareholders Meeting on May 25, 2022
20103010 Biotechnology
Other subject
29 Apr 2022
22:10 CEST
GENFIT
GENFIT : Mise à disposition du Document d’Enregistrement Universel 2021, du Rapport Annuel Form 20-F 2021 et de la documentation préparatoire à l’Assemblée Générale Mixte du 25 Mai 2022
20103010 Biotechnology
Other subject
20 Apr 2022
22:10 CEST
GENFIT
GENFIT Annual Combined General Meeting of May 25, 2022 — Availability of Preparatory Documents
20103010 Biotechnology
General meeting / Board Meeting
20 Apr 2022
22:10 CEST
GENFIT
GENFIT : Assemblée Générale Mixte du 25 mai 2022 — modalités de mise à disposition des documents préparatoires
20103010 Biotechnology
General meeting / Board Meeting
07 Apr 2022
22:10 CEST
GENFIT
GENFIT Reports Full-Year 2021 Financial Results and Provides Corporate Update
20103010 Biotechnology
Other subject
07 Apr 2022
22:10 CEST
GENFIT
GENFIT : Résultats financiers annuels 2021 et point sur les activités de la Société
20103010 Biotechnology
Other subject
28 Feb 2022
22:10 CET
GENFIT
GENFIT Annonce un Chiffre d’Affaires et une Position de Trésorerie robustes au 31 décembre 2021
20103010 Biotechnology
Other subject
28 Feb 2022
22:10 CET
GENFIT
GENFIT Announces Solid Revenues and Cash Position as of December 31, 2021
20103010 Biotechnology
Other subject
24 Jan 2022
22:10 CET
GENFIT
GENFIT annonce son calendrier financier pour 2022
20103010 Biotechnology
Other subject
24 Jan 2022
22:10 CET
GENFIT
GENFIT: 2022 Financial Calendar
20103010 Biotechnology
Other subject
21 Jan 2022
22:10 CET
GENFIT
GENFIT : Bilan semestriel du contrat de liquidité contracté avec le Crédit Industriel et Commercial
20103010 Biotechnology
Other subject
21 Jan 2022
22:10 CET
GENFIT
GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
20103010 Biotechnology
Other subject
17 Dec 2021
07:15 CET
GENFIT
On heels of global strategic partnership announced today, GENFIT acquires rights to novel asset
20103010 Biotechnology
Other subject
17 Dec 2021
07:15 CET
GENFIT
GENFIT : A la suite du partenariat stratégique global annoncé ce jour, GENFIT acquiert les droits pour un nouveau composé
20103010 Biotechnology
Other subject
17 Dec 2021
07:00 CET
GENFIT
GENFIT: Ipsen and GENFIT enter into exclusive licensing agreement for elafibranor, a Phase III asset evaluated in Primary Biliary Cholangitis, as part of a long-term global partnership
20103010 Biotechnology
Other subject
17 Dec 2021
07:00 CET
GENFIT
GENFIT : Ipsen et GENFIT concluent un accord de licence exclusif pour elafibranor, un composé évalué en Phase III dans la cholangite biliaire primitive, dans le cadre d’un partenariat global de long terme
20103010 Biotechnology
Other subject
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Paginazione
«
« First
‹
‹‹
1
2
3
Company press releases subscription
×
To subscribe to Press releases from this issuer, visit the Subscription to Company news section in
your account
section or
create an account
.
Home
Mercati
Amsterdam
Cash Products
Stocks
AEX index Stocks
AEX ESG Stocks
Indices
Funds
Bonds
ETFs
Structured products
Derivative products
Index options
Index futures
Stock options
Dividend derivatives
Stock futures
Quote Vendor Codes
Company regulated news
Latest
Archive
Brussels
Cash products
Stocks
Euronext regulated
Euronext Growth
Euronext Access
Expert Market
BEL 20 Stocks
Indices
Bonds
ETFs
Structured Products
Derivative products
Index futures
Stock options
Stock futures
Dividend derivatives
Quote Vendor Codes
Company regulated news
Latest
Archive
Expert Market
Dublin
Stocks
Euronext regulated
Euronext Growth
ISEQ 20 Stocks
Indices
Funds
Bonds
Irish Government Bonds
DOL
Lisbon
Cash Products
Stocks
Euronext regulated
Euronext Access
PSI Stocks
Indices
Bonds
Derivative products
Index futures
Stock options
Stock futures
Dividend derivatives
Quote Vendor Codes
Company regulated news
Latest
Archive
Milan
Cash Products
Azioni
Euronext Milan
Euronext Growth Milan
Euronext Star Milan
Euronext Global Equity Market
EuroTLX
Trading After Hours
MIB ESG Azioni
Bonds
MOT
Euronext Access Milan
EuroTLX
Structured Products
SeDeX
EuroTLX
ETFs
Fondi
Derivative products
Tutti
Futures su indici
Opzioni su indici
Opzioni su azioni
Futures su azioni
Dividend futures
Quote Vendor Codes
IPOs
Oslo
Cash Products
Stocks
Oslo Børs
Euronext Growth
Euronext Expand
Top performers
OBX stocks
OBX ESG Stocks
OSEBX stocks
OSEFX Stocks
Seafood Stocks
Shipping Stocks
Equity indices
Bonds
Oslo Børs
Nordic Alternative Bond Market
Bond indices
ETFs
Funds
Derivatives
Derivative products
Quote Vendor Codes
Company regulated news
Latest
Archive
Financial calendars
Primary insiders
Paris
Cash Products
Stocks
Euronext regulated
Euronext Growth
Euronext Access
CAC 40 Stocks
CAC 40 ESG Stocks
Indices
Bonds
ETFs
Structured products
Derivative products
Index futures
Index options
Stock options
Stock futures
Dividend derivatives
Quote Vendor Codes
Company regulated news
Latest
Archive
Azioni
All Markets directories
All Markets
Euronext regulated
Euronext Growth
Euronext Access
Euronext Expand
Euronext Global Equity Market
EuroTLX
Trading After Hours
Company regulated news
Latest
Archive
IPOs
All IPOs
Listing sponsors
Euronext Tech Leaders
Family business
Indices
Directory
ESG indices
Indices documents
Indices news
Index consultations
Contact Euronext indices
ETFs
Directory
ESG ETFs
Funds
Directory
ESG Funds
Oslo Mutual Funds
Fixed Income
ESG Bonds
1.5° Bonds
All Markets directories
All Markets
Amsterdam
Brussels
Dublin
Lisbon
Oslo
Milan
Paris
Structured Products
Directory / search
Bid-Only trading status
Trading Turbos in the Netherlands
Equity Derivatives
Index Futures
Index Options
Stock Options
Stock Futures
Dividend Derivatives
ETF Options
Contracts specifications
Tick Sizes
Wholesale Trading
Quote vendor codes
Commodities
Quotes
Quotes snapshot
Milling Wheat futures
Rapeseed futures
Corn futures
European Durum Wheat Futures
Milling Wheat options
Rapeseed options
Corn options
Trading calendars
Delivery
Wholesale Trading
Commitments of Traders (CoT) report
Contracts specifications
Quote vendor codes
Knowledge Centre
Bid & Ask
Options Investing E-learning
Contract Specifications
Position Management
Intrinsic Value
Premium & Valuation
Moneyness
Positions
Euronext News
Resources
Statistics & reports
Quality of execution
Trading hours & Holidays
Contract specifications
Quote vendor codes
Key Information Document
Class level
Product group level
Notices / Corporate actions
Cash Notices / Corporate actions
Derivatives corporate actions
All Corporate Actions
Latest
Unusual Contract Sizes, Dividends
Corporate Action Services
Corporate Action Policies
Derivatives notices
Market events
Suspended instruments
Stressed Market Conditions
Breach of Double Cap limits
Exceptional Market Conditions
Miscellaneous short messages
Market status
Members list
Issuers compliance
Where to find